ArticleProceedings of the National Academy of Sciences of the United States of America2015

CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.

Ariane Hammitzsch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.